By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Paratek Pharmaceuticals, Inc. 

75 Park Plaza
4th Floor
Boston  Massachusetts  02116  U.S.A.
Phone: 617-807-6600 Fax: 617-275-0039


Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria.

Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.

Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris. Top line data are expected in the first half of 2017.

Board of Directors
Michael F. Bigham
Chairman of the Board and Chief Executive Officer

Evan Loh, MD
Director and President, Chief Medical Officer

Thomas J. Dietz, Ph.D.

Timothy Franson, M.D.,

Richard Lim

Kristine Peterson

Robert Radie

Jeffrey Stein, Ph.D.

Last Updated: 04-23-02

Key Statistics

Ownership: Public

Web Site: Paratek Pharma
Employees: 76
Symbol: PRTK




Tufts University 

Company News
Paratek Pharma (PRTK) To Host R&D Day On November 17, 2016 10/26/2016 8:53:51 AM
Paratek Pharma (PRTK) To Report Third Quarter 2016 Financial Results And Provide Update On Clinical Progress On November 2, 2016 10/24/2016 8:12:17 AM
Paratek Pharma (PRTK), U.S. Department Of Defense Enter Research Agreement To Study Omadacycline Against Biodefense Pathogens 10/11/2016 7:55:58 AM
Paratek Pharmaceuticals, Inc. (PRTK) To Ring Nasdaq Closing Bell Recognizing 20th Anniversary 10/4/2016 7:58:01 AM
Paratek Pharmaceuticals, Inc. Initiates Phase 3 Study Of Oral-Only Omadacycline In ABSSSI 8/15/2016 12:09:33 PM
Paratek Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial And Operating Results 8/4/2016 11:03:28 AM
10 Biotech Stocks Analysts are Upbeat About in May 5/23/2016 8:24:58 AM
Paratek Pharmaceuticals, Inc. To Present Clinical Findings At ECCMID 2016 3/30/2016 10:37:18 AM
Paratek Pharmaceuticals, Inc. Expands Leadership Team 12/3/2015 7:53:30 AM
Paratek Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial And Operating Results 11/12/2015 8:35:16 AM